Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide Added to MDI in Overweight Type 2 Diabetes
NCT02113332Phase 2Completed
- Sponsor
- Region Västra Götaland
- Start
- Jan 2013
- Primary completion
- Aug 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Liraglutide with Placebo (2 arms). Primary endpoint: Change in HbA1c at 24 weeks. Started Jan 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02113332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113332.